Some people benefit from supplements like L-carnitine for symptoms like fatigue, pain, and depression
Figure 1 In line with these observations, weight loss has emerged not only as a supportive strategy but also as a disease-modifying intervention in PsA ( Preclinical studies further suggest that GLP-1RAs may modulate key cytokine pathways implicated in psoriatic disease, including NF-B, IL-6, IL17, and IL23, while small clinical studies have reported improvements in skin disease severity in PsO ( This narrative review summarizes the current clinical evidence on GLP-1RAs in PsO and PsA and discusses future research directions aimed at evaluating their potential role in intercepting PsA development and improving outcomes in patients with complex immunometabolic profiles
YOU AND WE (ON BEHALF OF OURSELVES AND OUR CONTENT PROVIDERS AND OTHERS ASSOCIATED WITH THIS SITE) AGREE THAT THE FOREGOING LIMITATION OF LIABILITY IS AN AGREED ALLOCATION OF RISK BETWEEN YOU AND US (AND OUR CONTENT PROVIDERS AND OTHERS ASSOCIATED WITH THIS SITE) AND REFLECTS THE FEES, IF ANY, WE CHARGE YOU TO USE THIS SITE, THE SERVICES AND THE CONTENT
Quick Answer: Current limited evidence does not suggest GLP-1 agonists directly worsen Crohn's disease, but their gastrointestinal side effects may complicate symptom monitoring and disease assessment
